Crohn’s Disease of the Esophagus, Duodenum, and Stomach

David M. Schwartzberg, MD1 Stephen Brandstetter, MD1 Alexis L. Grucela, MD, FACS, FASCRS2

1 Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio
2 Division of Colon and Rectal Surgery, New York University Langone Medical Center, New York, New York


Abstract

Upper gastrointestinal Crohn’s is an under-reported, under-recognized phenotype of Crohn’s disease. Routine screening in the pediatric population has shown a higher prevalence compared with adults; however, most adult patients remain asymptomatic with respect to upper gastrointestinal Crohn’s disease. For the patients who are symptomatic, medical treatment is the first line of management, except for cases of obstruction, perforation, or bleeding. Though most patients respond to medical therapy, mainly steroids, with the addition of immunomodulators and more recently biologics agents, surgical intervention is usually required only for obstructing gastroduodenal disease secondary to strictures. Strictureplasty and bypass are safe operations with comparable morbidity, although bypass has higher rates of dumping syndrome and marginal ulceration in the long term. Rare cases of gastroduodenal fistulous disease from active distal disease may involve the stomach or duodenum, and esophageal Crohn’s disease can fistulize to surrounding structures in the mediastinum which may require the highly morbid esophagectomy.

Keywords ► Upper Gastrointestinal Crohn’s Disease ► gastroduodenal Crohn’s disease ► esophageal Crohn’s disease ► strictureplasty

Since Crohn and colleagues first identified and categorized “regional ileitis” as a disease solely of the small bowel in 1932, subsequent literature has characterized an epithet for Crohn’s disease (CD) as occurring anywhere from oral cavity to anus.1 The vast literature reported on CD has been sparse on upper gastrointestinal (UGI) involvement by CD, defined as esophagitis, gastritis, and duodenitis, which was first expanded to include UGI pathology by Comfort et al in 1950.2-4 Research has shed light on the natural history of CD; however, it remains an idiopathic chronic inflammatory bowel disease (IBD) originating from a complex relationship of environmental, microbial, and genetic factors.5-6 CD makes up one of the two predominant classifications of IBD along with ulcerative colitis (UC) and indeterminate colitis (IC) having features of both. Historically, UGI-IBD was synonymous with CD; however, UC has been implicated with pathology in the proximal GI tract as well.7 Both CD and UC typically affect distal bowel with UC predominantly manifesting in the colon and rectum, and CD primarily in the distal small bowel (terminal ileum).

The prevalence of CD in North America in recent studies is 26 to 198 cases per 100,000 persons, with an incidence of 3.1 to 14.6 per 100,000 person-years.5,8,9 CD has a slight female predominance in North America.5 The age of onset for both CD and UC fits a bimodal distribution around ages 20 and 50 years. Studies have shown a predominant age of onset for CD in the lower age peak of the classic bimodal distribution, or have shown a unimodal distribution near age 20 years.5

Upper Gastrointestinal Involvement in IBD

Upper gastrointestinal CD is uncommon and has been reported to range from 0.3 to 5% of affected adult patients. Though under-reported, and overall less frequent than ileal disease, Goodhand et al examined UGI-CD, and found that it is more frequent in the adolescent literature, which could be
secondary to more frequent upper endoscopy, with almost 28% of adolescent CD patients having UGI involvement.10 Significantly earlier onset of CD has been found in patients with predominant UGI-CD at diagnosis,11,12 and pediatric patients with CD have a higher incidence of UGI-CD.13,14 A study of use of prospective esophagogastroduodenoscopy (EGD) in adult IBD patients showed the incidence of foregut CD was 41% in patients with previously confirmed CD and only 32% of patients were symptomatic.15 A study 20 years prior where prospective EGD was undertaken on 41 patients showed 56% of CD patients to have endoscopic abnormalities including aphthoid erosions, ulcers, and mucosal thickening.16 Granulomas were found in only 20% of specimens, with some literature reporting a range between 4 and 83%, and are therefore not diagnostic in UGI-CD.17 Granulomas were, however, more frequently found in patients who had other concomitant endoscopic abnormalities than without (26 vs. 11%).17 The differential for upper GI granulomatous disease is vast and some differentials are Helicobacter pylori, peptic ulcer disease, gastric carcinoma, gastric lymphoma, sarcoidosis, tuberculosis, and syphilis, among others listed in Table 1.17 Patients with UGI-CD manifestations have been shown to have higher rates of structuring disease, penetrating disease, recurrences, hospitalizations, and surgical interventions; thus, UGI-CD is somewhat of an overall prognostic factor for CD.18,19 In a study by Sakuraba et al., 70% of patients with distal CD and any UGI symptoms (epigastric pain, reflux, nausea, physician discretion) who underwent diagnostic EGD were found to have CD-related pathology.20 These findings make clear that foregut symptomatology requires further evaluation in patients with CD.

EGD with biopsy is also recommended in patients who have a clinical picture concerning for IBD, but who are deemed indeterminate after evaluation including clinical examination, laboratory and radiographic tests, and colonoscopy with biopsy and histologic examination, as this may aid in clarifying the diagnosis.21 Castellaneta et al undertook prospective EGD of 65 children with CD, finding a 31% rate of asymptomatic UGI-CD.22 These findings helped clarify the diagnosis in 11 of 13 IC patients. Due to this higher prevalence and the high rate of silent UGI-CD found in this and other prospective endoscopic studies, this study concluded that UGI endoscopy should be routine in the evaluation of all pediatric patients with CD. Another report comparing CD and UC biopsy results during EGD in pediatric patients showed a problematically high rate of histological changes in UC patients including significantly more intraepithelial lymphocytes for UC patients, emphasizing the importance of a skilled pathologist needed for the differentiation of these diseases.23 Current recommendation from the ESPGHAN Revised Porto Criteria for all children and adolescents diagnosed with IBD include EGD and ileocolonoscopy with histology and imaging of the small bowel.24

Isolated UGI manifestations of CD are uncommon. One study found only 0.8% isolated UGI manifestations in a series of 877 patients with CD.25 A larger study found that 13% of 1,015 patients reviewed retrospectively from a clinical database had UGI manifestations of CD, and only 2.5% had isolated UGI disease.25 In this study, increased age at diagnosis correlated with lower rates of UGI manifestations and more predominant colonic disease. This again established an association between UGI involvement, earlier age of onset, and more aggressive overall phenotype.

Symptomatology of CD is vast; however, UGI-CD presents most commonly with upper abdominal pain, obstruction, and occasionally massive bleeding.21,26 UGI-CD is uncommonly the first sign of CD, and, when diagnosed, is usually synchronous with active disease elsewhere in the GI tract, most commonly ileocolic involvement.26 In addition, it generally presents as contiguous disease from the proximal jejunum and usually involves the duodenum and stomach serially.3 Treatment for CD is primarily medical for acute flares and maintenance therapy; however, surgery is a cornerstone of CD management for complications such as uncontrolled bleeding, perforation, fistulae, and obstruction. Surgery for CD of the small bowel, colon, and rectum involves resection, stricture-plasty, diversion, or a combination of these. Operating on UGI-CD has its own set of challenges. This is mainly due to its proximal location with limited access, and structural relationship to other key organs in the GI tract.

**Table 1** Differential diagnosis in upper gastrointestinal Crohn’s disease

<table>
<thead>
<tr>
<th>Gastroesophageal reflux</th>
<th>Helicobacter pylori</th>
<th>Hypertrophic gastropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pill-contact ulcers</td>
<td>Cytomegalovirus</td>
<td>Eosinophilic gastritis</td>
</tr>
<tr>
<td>Malignancy</td>
<td>Behcet’s syndrome</td>
<td>Wegener’s granulomatosis</td>
</tr>
<tr>
<td>Fungal disease</td>
<td>Gastric lymphoma</td>
<td>Food and suture granulomas</td>
</tr>
<tr>
<td>Viral esophagitis</td>
<td>Sarcoidosis</td>
<td>Histoplasmosis</td>
</tr>
<tr>
<td>Herpes simplex virus</td>
<td>Tuberculosis</td>
<td>Whipple’s disease</td>
</tr>
<tr>
<td>Epidermolysis bullosa</td>
<td>Syphilis</td>
<td>Idiopathic isolated granulomatous gastritis</td>
</tr>
</tbody>
</table>

**Classification and Diagnosis of Upper Gastrointestinal IBD**

The diagnosis of IBD depends on clinical, radiographic, endoscopic, and histologic factors. Attempts to formalize the classification have been made at the Rome, Vienna, and Montreal Working Parties.27,28 The first two of these meetings created the ALB (age, location, and behavior) criteria for classification of CD, while the Montreal classification created finer stratification by age as well as allowing for the classification of patients with several concurrent areas of active disease.27 UGI-CD is specified as L4 in this classification schema, and is used as a modifier to L1–L3 disease so that the classification captures all areas of disease. The L4 classification includes a large strata of the CD population with...
wide ranges of disease severity in the upper GI tract and elsewhere.

Many attempts have been made to integrate serologic criteria into the diagnosis of IBD. While serologic studies can be suggestive of different disease processes, all lack sensitivity and consequently are of limited diagnostic benefit. The common serum antibodies tested in this workup include perinuclear antineutrophil cytoplasmic antibody (pANCA), anti-Saccharomyces cerevisiae antibody (ASCA), anti-outer membrane porin C antibody (anti-OmpC), and anti-CBir1 flagellin antibody (anti-CBir1). Combined ASCA immunoglobulin G or immunoglobulin A positive and pANCA negative serology has sensitivity and specificity of 55 and 93% for CD, and pANCA positivity with no ASCA measurement has sensitivity and specificity for UC of 55.3 and 88.5%, respectively (Reese 2006). Numerous studies have also found various serologies to suggest different patterns of CD or to correlate to disease severity or need for surgery.29–33

There are no known serologies to distinguish location or UGI involvement. Serologic studies have been evaluated for their ability to determine a diagnosis in those patients labeled initially as IC. Indeterminate colitis is a variant of IBD, which does not fully fit the diagnostic picture of either CD or UC, though in many cases it eventually takes the phenotypic characteristics of either CD or UC. While serologic studies are often used to fill in a full clinical picture to suggest a clearer diagnosis, the use of EGD in cases of IC can define the disease and lead to better medical management.21,22

**Gastroduodenal Crohn’s Disease**

The first report of duodenal CD was described by Gottlieb and Alpert in 1937, followed by Ross who reported gastric CD in 1949.34,35 Gastroduodenal Crohn’s occurs in 0.5 to 4% of patients with CD and is most commonly associated concomitantly in the distal small bowel and colon.3,17 Yamamoto et al found that 56% of patients diagnosed with gastroduodenal CD had previous CD elsewhere in the GI tract, while in 35% of cases gastroduodenal CD was diagnosed synchronously with distant disease.36 Less than one-third of patients will have isolated gastroduodenal disease at the time of diagnosis and most will develop distal disease later in life.3,17 A study performed at the Lahey Clinic involving 89 patients showed 92% of patients with primary gastroduodenal CD had developed distal disease within a follow-up of 11.7 years.26 UGI-CD is often asymptomatic and therefore is diagnosed infrequently in adults compared with pediatric patients where UGI endoscopy is performed routinely.4,11 However, even with UGI-CD remaining largely asymptomatic, some advocate for routine endoscopy of the upper GI tract to determine the presence and extent of UGI-CD, and to help distinguish UC from CD in cases that are difficult to diagnose based on presence of distal disease.15,37–39

Gastroduodenal CD is almost equally common in both genders with a male:female ratio of 1.2:1.3,4 Adult Crohn’s gastritis is usually mild and presents with inflammation, which is usually responsive to medical management. Although Crohn’s gastritis occurs most commonly in adults during the third and fourth decades of life, pediatric cases have been reported.3,4 This can manifest as inflammation (gastroduodenitis), fistula, obstruction/stricture, or a combination of these.

Pediatric Crohn’s gastritis is often asymptomatic and is usually diagnosed on routine endoscopy.6,17 Reports of focally enhanced gastritis (FEG) in the pediatric literature have demonstrated an association with FEG and CD and have shown limited association with UC. A retrospective study from Roka et al examined pediatric upper endoscopy in patients with CD (n = 185) and in patients without CD who required endoscopy for upper abdominal complaints (n = 684). FEG was found significantly more frequently among children with IBD than without (35.7 vs. 3.4%, respectively, p < 0.001), and all types of IBD had higher frequencies of FEG compared with non-IBD (CD 54.1%, UC 21.6%, IBD unclassified 18.4%, p < 0.001).40 In addition, FEG had a sensitivity and specificity of 35.7 and 96.6% in distinguishing IBD from non-IBD patients and a sensitivity and specificity of 54.1 and 78.4%, respectively, for discriminating CD from UC. There was, however, no correlation with the presence of FEG and lower GI IBD.40

Crohn’s gastritis is the most common site of UGI-CD, being identified 50% of the time in the initial disease presentation of the upper GI tract; however, it is often clinically associated with Crohn’s duodenitis and therefore often referred to as “gastroduodenal CD.”48,17 Some authors have found that the gastritis is most commonly (60%) continual with the duodenum, starting in the gastric antrum and progressing distally to the proximal duodenum.17 Yamamoto et al described the most frequent sites of gastroduodenal involvement as duodenal bulb inflammation with or without gastric involvement, with only 28% of patients having isolated disease distal to the first part of the duodenum.41

Gastroduodenal fistulas have a slight male predominance in duodenocolic fistulas, and no gender distribution differences for gastric fistulas. Both present with abdominal pain, diarrhea, and weight loss. Feculent vomiting may be encountered secondary to gastrocolic fistulas in which the site of active Crohn’s is distal disease and the duodenum/stomach is not involved primarily, that is, ileal–duodenal fistula, where only the ileal disease needs resecting, or duodenocolic fistula where patients have had previous ileocolic resections and had disease recurrence just proximal to the anastomosis leading to duodenal disease.3,19,42 Primary gastroduodenal fistulas are exceedingly rare with a reported incidence of less than 0.6%, and the stomach or duodenum is likely to be involved as a target organ from a fistula originating more distally such as the terminal ileum or transverse colon. A study by Van Patter et al examining 600 patients reported a 0.3% incidence.3,43,44 Gastric fistulas usually originate from the transverse colon and typically involve the greater curvature of the stomach, while duodenal fistulas form from adjacent colon or ileocolic anastomosis to the second and third portions of the duodenum.3,36,45 Treatment by take-down of the fistula, debridement, and mobilization of the stomach and/or duodenum, followed by primary repair with one or two layers, is generally sufficient; however, jejunal serosal patches have been reported as a technique.3,45

**Clinics in Colon and Rectal Surgery** Vol. 32 No. 4/2019

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
described duodenoejunosutostomy for a duodenal fistula/defect
without any reported complications; however, reports from
Yamamoto et al and Jacobson et al show that primary closure
without tension is sufficient.3,45–47

The symptomatology of gastroduodenal CD varies and is
largely dependent on any degree of obstruction present3,15,17,36,39,48. As
stated previously, gastroduodenal CD is commonly
asymptomatic in both the pediatric and adult litera-
ture.3,15,17,36,39,48 Many of the gastrointestinal symptoms
of UGI-CD mimic peptic ulcer disease and lower GI Crohn’s as
nonspecific epigastric pain, nausea/vomiting, and bloating3
(– Table 2). The most common symptom in gastroduodenal
CD in adults is epigastric abdominal pain, which is nonra-
diating, postprandial, and relieved by antacids and food.17,26
Nugent and Roy documented the symptoms of gastroduo-
denal CD, listed in decreasing frequency: pain, nausea,
vomiting, weight loss (>4.5 kg), melena, and fever.39 Lenaerts et al described the most common symptoms of pediatric
gastroduodenal CD being dysphagia, pain with eating, nau-
sea/vomiting, weight loss, and aphthous ulceration of the
oral cavity48,49 (– Table 3). Continued epigastric pain and/or
nausea and vomiting leading to weight loss is often a sign of
gastroduodenal stricture from chronic inflammation.3,17,48
Perforation and acute bleeding is much more commonly
associated with long-standing inflammation in peptic ulcer
disease, and not in CD. Both of these are exceedingly rare in
gastroduodenal CD, which occasionally results in chronic,
nonacute bleeding leading to chronic anemia.1,39,50

**Evaluating Gastroduodenal Crohn’s Disease**

Radiographic findings can suggest CD or UC in the right
clinical setting. Positive findings on UGI studies are similar to
those found in lower GI CD, including wall thickening,
stenosis, obstruction, and ulceration. Findings such as ileitis
or colitis may be found on computed tomography (CT) scans
or magnetic resonance imaging (MRI) studies, but are non-
specific for IBD. These imaging studies are often useful in
the evaluation of patients with an acute abdomen, especially CT
which is often available to clinicians in an acute setting, or in
ruling out intra-abdominal abscess prior to the initiation of
anti-TNF therapy initiation. Due to the chronic nature of IBD,
the routine use of CT scan must be weighed for benefit
against the cumulative effects of ionizing radiation in these
patients.

Enterography is a useful adjunct for evaluating CD and can
help diagnose and localize areas of stricture disease
throughout the GI tract. MR and CT enterography are com-
parably useful diagnostic tests, with the former avoiding the
radiation of CT scan. Conventional fluoroscopic evaluation
uses about one-third the radiation of its CT equivalent, and is
more useful for disease limited to the mucosa. Gadolinium-
enhanced MRI and the use of diffusion-weighted imaging
may also provide some advantage in the differentiation of
fibrotic strictures and acute inflammation.51–54

The first pathology noted on double-contrast imaging are
aphthous ulcerations, followed by thickened rugal folds,
cobblestoning, pseudodiverticula, and strictures—evident
by a tubularization of the antrum, pylorus, and duode-
num.3,19 This scarring is secondary to chronic fibrosis,
and resembles a gastroduodenostomy for ulcer disease and
 coin-
ing the term “pseudo-Billroth 1 appearance.”3,11,17,55 A
“ram’s horn” sign is rare, but representative on contrast
imaging for antral and duodenal bulb disease.3,17,38,56 Upper
GI studies may also elucidate fistulas with the distal small
bowel and/or colon.

Though endoscopy can be essential to correct diagnosis of
UGI symptoms in CD, its use may be limited in patients with
acute abdomen. Diagnostic EGD in CD patients has 60 to 70%
rate of positive findings, and some authors advocate screening
EGD in all CD patients.20,57 Screening EGD is recom-
pended for pediatric patients with CD, as the rate of UGI-CD is
higher in this population and the presence of disease on
EGD may have implications regarding disease severity and
need for operation.13,14

Endoscopically, Crohn’s gastritis can produce a range of
morpheologic features both microscopically and macroscopi-
cally, but most commonly it is identified as superficial, mild,
and diffuse inflammation (– Table 4).4,15 A summary of the
locations and types of CD-related changes commonly seen on
EGD can be seen in –Fig. 1. The Montreal classification

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Symptoms of gastroduodenal Crohn’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common symptoms</strong></td>
<td><strong>Rare symptoms</strong></td>
</tr>
<tr>
<td>Epigastric pain</td>
<td>Anemia</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>Diarrhea</td>
</tr>
<tr>
<td>Anorexia/weight loss</td>
<td>Feculent vomiting (gastrocolic fistula)</td>
</tr>
<tr>
<td>Early satiety</td>
<td>Hematemesis</td>
</tr>
<tr>
<td>Belching</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Common presenting symptoms in gastroduodenal Crohn’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adult (Nugent and Roy,</strong></td>
<td><strong>Pediatric (Lenaerts et al,</strong></td>
</tr>
<tr>
<td><strong>n = 89)</strong></td>
<td><strong>n = 69)</strong></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Dysphagia</td>
</tr>
<tr>
<td>Weight loss</td>
<td>Pain with eating</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>Nausea/vomiting</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Weight loss</td>
</tr>
<tr>
<td>Bleeding/anemia</td>
<td>Aphthous mouth ulcers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Endoscopic findings in gastroduodenal Crohn’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edema</td>
<td>Erythema</td>
</tr>
<tr>
<td>Friability</td>
<td>Granularity</td>
</tr>
<tr>
<td>Erosions</td>
<td>Aphthous ulcers</td>
</tr>
<tr>
<td>Thickened folds</td>
<td>Mucosal nodularity/cobblestoning</td>
</tr>
<tr>
<td>Strictures</td>
<td>Fistulae</td>
</tr>
<tr>
<td>Pseudodiverticula</td>
<td>Luminal narrowing</td>
</tr>
</tbody>
</table>
defined microscopic features as focal-enhanced gastritis, focal crypt irregularity/crypt distortion, fissural ulceration and/or granulomas sans H. pylori infection, and macroscopic findings as erosions, aphthous lesions, ulcerations, and strictures.\textsuperscript{15,27} Crohn’s gastritis can display evidence of neutrophilic epithelial clusters termed “focally enhanced gastritis,” aphthoid ulcers, and noncaseating granulomas.\textsuperscript{4} It can also mimic the appearance of H. pylori infection and other classic signs and symptoms of peptic ulcer disease in both endoscopic and clinical findings.\textsuperscript{3} H. Pylori rates in the CD patient population are lower than that in the general population, possibly as a result of the regular antibiotic administration in this population.\textsuperscript{57,58}

Despite this, the testing of H. Pylori during EGD done for foregut complaints is still recommended, as the presence of this infection can cause concomitant inflammation with CD and a positive finding requires standard antibiotic treatment. Less commonly, duodenal CD can present with bleeding, pancreatitis, or common bile duct obstruction.\textsuperscript{3,37,50,59–62} In their series of CD patients who underwent EGD, Sakuraba et al found evidence of CD changes in the duodenal bulb of 32% of patients and the second portion of the duodenum in 18% of patients.\textsuperscript{20}

Recent studies have shown that although UGI inflammation associated with IBD was classically defined as UGI-CD, UC displays morphologic changes in the upper GI tract as well.\textsuperscript{4} It is therefore necessary to distinguish between CD and UC and their treatment algorithms will differ.

Nugent and Roy established criteria to diagnose UGI-CD specifically, which consisted of one of the following two criteria: (1) on pathology, the finding of noncaseating granulomatous inflammation of the duodenum with or without coexisting CD at other gastrointestinal tract sites, and without an alternative systemic granulomatous disorder, or (2) clearly documented CD as another gastrointestinal site and radiologic and/or endoscopic evidence of diffuse inflammatory changes suggestive of CD.\textsuperscript{39,48} The finding of a bamboo joint–like appearance in the stomach, characterized by longitudinal inflamed folds with perpendicular erosions and linear furrows, is also pathognomonic for CD.\textsuperscript{53} This finding, while relatively recognizable to endoscopists’ various skill levels, does not seem to correlate significantly with disease severity.

Endoscopic erosions are rare in UC, while granulomas are diagnostic of CD and not seen in UC. Aphthoid erosions and mild inflammation that infiltrates gastric glands are also classically associated with CD and not a feature of UC-related inflammation, so much so that if CD is ruled out, non-IBD

---

**Fig. 1** Manifestations of CD seen on EGD. (https://www.hindawi.com/journals/bmri/2014/610767/fig1/).\textsuperscript{20}
differentials like peptic ulcer disease and malignancy should be explored. Diffuse chronic duodenitis can be found in patients who had undergone colectomy with pouch reconstruction and suffered from pouchitis.

Furthermore, the presence of duodenitis may be predictive of pouchitis in UC patients, especially occurring shortly after total colectomy is performed. This association has been reported in several other cases as well, and in most reports both the duodenitis and pouchitis are readily treated with medical therapy alone. 

Table 2 lists typical findings of gastroduodenal CD on endoscopy. Neoplasms may appear as CD and must be ruled out, as well as limitis plastica, lymphoma, and locally advanced T4 tumors of the upper GI tract invading the gastroduodenum.

Medical Management of Gastroduodenal Crohn’s Disease

Gastroduodenal CD is initially managed medically, if possible, paralleling the treatment of CD elsewhere in the GI tract. A step-wise treatment approach is generally used, where more powerful immunosuppressive agents are added only if the patient progresses through treatment. Juxtapose to a step-wise approach, a top-down approach has been popularized since biologic therapy was added to the armamentarium of IBD treatment. Top-down medical treatment involves initially starting the patient on immunosuppressants and biologics and de-escalating medications as the patient improves; this has led to decreased rates of hospitalizations and operative intervention, however, exposes the patients to overtreatment.

For UGI-CD, antacids, with either histamine (H2) blockers or proton pump inhibitors, are a mainstay of treatment, especially while working up differentials such as gastritis, gastroesophageal reflux disease, or peptic ulcer disease. Antacids may not confer histologic evidence of improvement; however, they do provide symptomatic relief and limit further mucosal damage by gastric acid on possible gastroduodenal CD. Next, if necessary, treating H. pylori is paramount once its presence and eventual eradication is confirmed.

Though data are scarce on its relationship to UGI-CD symptoms, most patients are treated with standard CD regimens such as 5-aminosalicylic acid, azathioprine, 6-mercaptopurine, methotrexate, and steroids. The pro-drug sulfasalazine is not active until in the distal ileum or colon, when it is active in the form 5-aminosalicylic acid, and therefore will have limited used in upper GI disease. Mesalamine is pH dependent and although a slow-release formula called Pentasa is released in the proximal small bowel, its major absorption will be distal to UGI-CD. Although Korelitz et al in 1993 reported marked improvement or complete healing in 100% of patients with nonsteroid therapy, the exact combination for medically induced remission of UGI-CD is not known and must be tailored to each patient; however, steroids do appear to confer a durable clinical response. Griffiths et al reported a moderate clinical response in 10 patients with gastroduodenal disease treated with oral corticosteroids along with 6-mercaptopurine and H2-receptor blockers in 1 and 3 patients, respectively.

Nugent and Roy reported an excellent response in 91% of patients treated with steroids for nonobstructing gastroduodenal disease; however, some were also being treated with sulfasalazine, H2-blockade, azathioprine, or metronidazole. Even with moderate to excellent clinical responses with steroids, the presence of obstruction is usually a prognostic sign that operative intervention will be needed. If patients continue to display symptoms while on steroid treatment, or require maintenance therapy, the immunomodulators azathioprine and 6-mercaptopurine can be used as adjuncts, but the evidence supporting this treatment is limited and anecdotal.

In a subgroup analyzed from a 20-year experience by Korelitz et al, they reported complete therapeutic goal achievement in healing or marked improvement in patients with gastroduodenal disease treated with 6-mercaptopurine. Miehsler et al showed that in 12 patients with gastroduodenal CD treated with prednisone and azathioprine, the prednisone could be discontinued in over half of them (n = 7) after 4 to 6 months.

The role of infliximab on gastroduodenal CD is not defined, as only small studies have shown any success, even though its use in distal CD has been well established. Kawachiya et al have the largest series, consisting of three patients all treated with infliximab for gastroduodenal CD; two patients had ileocolic disease as well. Their patients not only had symptomatic relief but also had evidence of macroscopic healing without any adverse effects, suggesting that infliximab treatment for gastroduodenal CD is safe, effective, and may obviate the need for invasive interventions. Firth et al published a report of a case of severe gastroduodenal disease with diffuse thickening and ulceration that responded to infliximab therapy, while Grübel et al showed resolution in one patient treated with infliximab, while a different patient with gastroduodenal disease was a nonresponder.

Prior to considering surgery, endoscopic intervention can be used to treat fibrotic strictures of gastroduodenal outflow. As stated previously, obstructive features with gastroduodenal CD are associated with high failure rates of medical management; however, advancements in endoscopic therapy have alleviated the need for surgery in some instances. Endoscopic balloon dilation has been shown to provide durable relief in several studies. Lower GI stent deployment has been described to stent across a fibrotic stenotic segment of bowel. However, it has not been studied for UGI Crohn’s lesions.

Murthy successfully treated a case of gastric outlet obstruction secondary to gastroduodenal CD, in which three endoscopic hydrostatic dilations were performed over a 3-year period and yielded symptomatic relief for over 2 years at a time. Matsui et al treated five patients with balloon endoscopic dilation in a regimen that included multiple dilations within a few weeks’ period, in which each session involved multiple dilations using 10-, 12-, 15-, 18- and 20-mm balloons. Sixty percent of their patients had recurrent symptoms within a 3.4-year follow-up; however, all were able to avoid surgery. Rana et al reported success with dilatation with intralesional steroid (triamcinolone 80 mg) injection in a patient who could not receive immunomodulators due to pulmonary tuberculosis.

Table 2

<table>
<thead>
<tr>
<th>Antacids</th>
<th>H2-receptor blockers</th>
<th>6-mercaptopurine</th>
<th>Azathioprine</th>
<th>Metronidazole</th>
<th>Sulfasalazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
<td>Present</td>
</tr>
</tbody>
</table>

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
In all cases of CD, especially those with obstruction, timely nutritional assessment and supplementation can be critical to the patient’s outcome. Elemental enteral nutrition (EEN) has been shown to induce anti-inflammatory effects in small bowel CD, and can prolong remission in those able to tolerate it. The use of nasojejunally administered EEN has been studied for use in inducing remission in children and was found in an early study to be equally efficacious to high-dose steroids with better weight gain profile during treatment, and subsequent studies have confirmed the efficacy of this treatment.82

This effect was reported to be especially successful for pediatric patients with UGI-CD.83

The most recent introduction of polymeric formula EEN was found to have a more palatable flavor, allowing for the avoidance of nasojejunal feeds in some patients. Similar studies in adults have shown less impressive results, though a significant part of this may be due to poor compliance.84,85

While enteral nutrition is ideal and provides manifold benefits with a lower risk profile, some selected situations still require the administration of total parenteral nutrition (TPN). Proximal enterocutaneous or enterenteric fistulas, short bowel syndrome, and certain cases of obstruction which are not immediately amenable to surgical treatment may require TPN. While TPN is certainly more expensive than typical enteral nutrition, certain formulations of EEN may be comparably expensive. Nevertheless, the long-term sequelae of TPN administration include high risk of Central Line-Associated Bloodstream Infection (CLABSI), liver disease, and central access complications; therefore, all attempts to maintain adequate enteral nutrition should be made. Though medical and surgical management has seen tremendous advancements as the disease has been extensively studied, the idiopathic chronic nature of CD remains largely unpredictable and a treatment challenge.

**Surgical Management for Gastrointestinal Crohn’s Disease**

Surgical management for gastroduodenal CD remains the only option for patients with ongoing symptoms, mainly obstruction, fistula, or pain.18 The most common indications for operative intervention in gastroduodenal CD are gastric outlet obstruction (83%), refractory pain (11%), and bleeding (5%)3 (Table 5). Many surgical procedures have been described, all with various outcomes and side effects; however, historically gastrojejunostomy with vagotomy is the most popular procedure performed.86 Antiulcer procedures such as antrectomy, vagotomy and Billroth I or II reconstruction, gastroenterostomy with or without vagotomy, gastro-duodenostomy, duodenojejunostomy, stricturoplasty, and, more recently, laparoscopic approaches to these procedures have been described.3,87,88 Murray et al highlighted the safety of bypass procedures such as gastrojejunitomy, duodeno-jejunostomy, and gastroduodenostomy, over gastric and duodenal resection. They report low morbidity, though one-third of their patients required reoperation for marginal ulcer or reobstruction.19 Routine vagotomy should not be employed with all bypass procedures according to Nugent and Roy.39 Murray et al concluded that this decision must be individualized and likely avoided in CD patients with chronic severe diarrhea, significantly decreased small bowel length, or resection of the ileocecal valve.19

Resection is complicated with high morbidity, and difficulty with wide kocherization of the duodenum in the setting of a chronically inflamed retroperitoneal duodenum. These concerns led to surgeons exploring stricturoplasty. Being able to find healthy, noninflamed, jejunum can also present a challenge for gastro- or duodenojejunostomy, and in that case, stricturoplasty is preferable. Lastly, concerns with malignancy in bypassed segments resulting from chronic inflammation or blind loop syndrome in the bypassed limb were all reasons stricturoplasty was attempted initially for gastric outlet obstruction.3

Stricturoplasty also remains an effective option for obstructing duodenal disease, but mixed success has been reported. It is advocated by Worsey et al who treated 34 patients with 37 strictures.86 Overall, 21 patients had bypass procedures and 13 had stricturoplasty, with the two groups having a mean follow-up of 8 and 3.5 years; respectively. Reoperation rates were similar in both groups: 2 out of 13 or 15% in the stricturoplasty group, and 2 out of 21 or 10% in the bypass group. The authors decided to perform stricturoplasty over bypass whenever possible, as marginal ulceration, dumping syndrome, and delayed gastric emptying (only in the bypass group) were higher in the bypass group. However, 100% of patients in both groups described symptomatic improvement and had durable results.86

Yamamoto et al retrospectively reviewed 13 patients who underwent stricturoplasty (and 4 patients who underwent pyloroplasty) for obstructive duodenal CD.41 Two patients developed anastomotic dehiscence and were treated with Roux-en-Y bypass, while one patient had prolonged obstruction and eventually required gastrojejunostomy. Later on, six patients developed repeat strictures and of those six, five required repeat stricturoplasty and one required duodeno-jejunostomy. Overall, nine out of thirteen patients needed reoperation after stricturoplasty. This led to the conclusion that stricturoplasty for duodenal CD is fraught with a high incidence of postoperative complications and restricture.

**Table 5** Indications for operation in gastroduodenal Crohn’s disease

<table>
<thead>
<tr>
<th>Publications</th>
<th>Obstruction</th>
<th>Pain</th>
<th>Bleeding</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worsey et al (n = 34)</td>
<td>32</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Nugent and Roy (n = 33)</td>
<td>23</td>
<td>9</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Yamamoto et al (n = 23)</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Murray et al (n = 22)</td>
<td>17</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Farmer et al (n = 10)</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>
compared with bypass.\textsuperscript{46,87} Because the literature is so limited and retrospective, there is no clear consensus on which operation is superior.\textsuperscript{3,46,86}

Campbell et al performed a meta-analysis comparing conventional (Heineke-Mikulicz and Finney) strictureplasty against several nonconventional options (modified Finney, combined Heineke-Mikulicz and Finney, modified Heineke-Mikulicz, and Michelassi) and found the modified options to generally provide lower rates of immediate and delayed complications.\textsuperscript{89} Consideration of alternate configurations should be part of the preoperative planning for complex strictureplasty. Sampietro et al noted that L4 disease can be amenable to nonconventional strictureplasty in their case, and showed that recurrence in this group is comparable to that of L1 and L3 disease.\textsuperscript{90}

Laparoscopic bypass with gastrojejunostomy has been described by Salky who reported 12 patients who underwent laparoscopic gastrojejunostomy, with two undergoing concomitant laparoscopic ileocolic resection for stenotic ileal disease.\textsuperscript{87} Eleven patients had resolution of symptoms and durability over 4.2 years. One patient had an anastomotic mechanical failure that required reoperation. They reported improved cosmetic result and shorter hospital length of stay, with no other morbidity or mortality.\textsuperscript{90,89}

Dysfunction of the ampulla with resultant pancreatitis and cholangitis has been reported in several series of CD patients.\textsuperscript{91–93} Treatments for this disease process may involve medical treatment of CD and endoscopic stent placement. In some cases, a pancreaticoduodenectomy may be indicated. In other cases, a pancreaticoduodenectomy may be amenable to nonconventional strictureplasty in their case, and showed that recurrence in this group is comparable to that of L1 and L3 disease.\textsuperscript{90}

Laparoscopic bypass with gastrojejunostomy has been described by Salky who reported 12 patients who underwent laparoscopic gastrojejunostomy, with two undergoing concomitant laparoscopic ileocolic resection for stenotic ileal disease.\textsuperscript{87} Eleven patients had resolution of symptoms and durability over 4.2 years. One patient had an anastomotic mechanical failure that required reoperation. They reported improved cosmetic result and shorter hospital length of stay, with no other morbidity or mortality.\textsuperscript{90,89}

\textbf{Crohn's Disease of the Esophagus}

Esophageal CD is the rarest form of foregut CD involvement first described by Franklin and Taylor in 1950, and congruently, there are limited literature and data regarding this entity.\textsuperscript{48,97} A large Mayo Clinic article examining 12,367 patient charts over 20 years found only 24 patients with esophageal CD (0.12%).\textsuperscript{98} As with gastroduodenal CD, there are disparities in the incidence of esophageal CD described between adult and pediatric patient populations, largely explained by the routine use of upper endoscopy in the adolescent population.\textsuperscript{98} The incidence and prevalence of esophageal CD reported in adults is 1.2 to 1.8% and 3.3 to 6.8%, respectively, with pediatric incidence and prevalence being 25.8 to 41.5% and 7.6 to 17.6%, respectively.\textsuperscript{98–102} The prevalence in adolescent patients is reported to range between 33 and 43%.\textsuperscript{39,101}

The challenges of diagnosing and reporting Crohn's esophagitis exist for two main reasons: first, esophageal CD resembles symptoms as erosive esophagitis or acid reflux; and second, the nonspecific histologic findings make esophageal CD difficult to distinguish. (\textsuperscript{–Table 1}) The most common symptoms of Crohn's esophagitis are reported by De Felice et al, and include dysphagia (54%), odynophagia (33%), epigastric pain (33%), acid reflux (25%), and chest pain (13%).\textsuperscript{98} Again, diagnosis is challenging as many of these symptoms are indistinguishable from acid reflux or pill-induced contact ulcers.\textsuperscript{3,4} Occasionally, patients initially present with advanced disease, presenting with fistulas, progressive dysphagia, and strictures secondary to chronic inflammation. The median time between CD diagnosis and esophageal involvement is reported to be 3 years; however, in cases where upper endoscopy was performed during the initial diagnosis of CD, 43% of patients had evidence of esophageal CD at that time.\textsuperscript{98} Twenty-one percent of patients who were diagnosed with esophageal CD also had synchronous gastroduodenal and ileocolic disease. There is also an association with oral ulcers, as 33% of patients with esophageal CD symptoms had evidence of oral ulcers of exam.\textsuperscript{98}

Endoscopy correlates with esophagus-specific symptoms, such as ulcerations, strictures, and fistulas, which were signs of advanced disease and seen in the majority of patients reported by De Felice et al.\textsuperscript{98} While granulomas are not frequently seen, with some reports describing granulomas in 0 to 21% of patients, aphthoid ulcers found in the setting of active inflammation are typically greater than what is seen with Crohn’s gastritis.\textsuperscript{4,48,98,102}

Authors have described the stages of esophageal CD based on endoscopy findings. The earlier stage consists of erythema, edema, aphthous ulcers, and granularity of the esophageal mucosa.\textsuperscript{48} The second, or advanced stage, consists of strictureing and stenosis, as stenosis is typically 1 cm in length or greater.\textsuperscript{48} De Felice et al reported the most common locations of esophageal involvement were 29% mid- and distal esophagus, 17% mid-distal, 21% diffuse involvement, and 4% proximal disease.\textsuperscript{98} Though only two patients had fistulizing disease and four patients had strictures, 75% of patients had inflammatory esophageal CD. Erythema and erosions were present half of the time, deep ulcerations in 13%, and pseudopolyps in 4%.\textsuperscript{98} Histology may also show "squiggle cells" which are dense intraepithelial lymphocytes which are not specific for CD, as celiac disease and reflux esophagitis share this feature. Eosinophilic esophagitis may also be present and is only distinguishable from Crohn’s-related esophagitis by the pathologic Th1-type response typical of CD as opposed to the Th2-type response in eosinophilic esophagitis.\textsuperscript{4} Though UC esophagitis shares features of CD with increased eosinophils, deep ulcerations and granulomas are not present with UC.

\textbf{Medical Treatment of Crohn’s Esophagitis}

The medical treatment of esophageal CD is analogous to gastroduodenal CD. As in gastroduodenal CD, a stepwise approach to multidrug therapy is usually needed; however, there are no long-term data on the optimal regimen. Most patients with esophageal CD have distal disease and are likely on maintenance therapy by the time they are diagnosed with esophageal CD; however, the addition of antacids (either H2 blockade or proton pump inhibitors), steroids, and 5-aminosalicylates are considered first-line treatment once esophageal disease is identified.\textsuperscript{3,48} Although esophageal
disease can be devastating, in the form of esophageal fistulas, the majority of patients are treated medically without the need for endoscopic or surgical intervention. Many immunomodulators are available as previously described, but many of them have low activity in the upper GI tract and therefore nomodulars are available as previously described, but many patients who failed previous therapies. In a series from De Felice et al, infliximab resulted in complete resolution in their cohort of five patients. Two additional patients were treated with infliximab after prednisone induction therapy without any documented recurrence. Infliximab was also shown to be effective in fistulizing esophageal CD, as an esophageal gastric fistula was successfully closed with follow-up endoscopy.

**Surgical Treatment of Esophageal Crohn’s Disease**

Surgery for esophageal CD is indicated for esophageal stenosis, obstruction, ulcerations, fistula, or malignancy. Stenotic lesions, advanced endoscopy with bougie or balloon dilatation has been effective and can delay or obviate the need for surgical intervention. Stenotic lesions can also be managed with electrosurgical division under direct endoscopy for symptom relief. Mathis et al described an esophageal CD stricture dilatation with concomitant fibrin sealant to manage an esophago-bronchial fistula with stricture for over 18 months. There are no reports of intraluminal steroid injection in esophageal CD patients in isolation; however, De Felice et al treated patients with combinations of dilatation, biologics, dapsone, steroid injections, steroid gel, and proton pump inhibitors. If ulceration forbids advanced endoscopic therapy, systemic treatment in combination with gastrostomy, either percutaneous or open, may allow the ulcer to heal while still giving enteral nutritional support. Stenting is also a therapeutic option but has not been widely studied.

Uncommonly, through case reports, esophageal CD can lead to fistulous formation to the tracheobronchial tree and mediastinum leading to complications such as airway issues, pneumonias, par aesophageal abscess, and mediastinitis. Past reports have examined esophagectomy in the setting of Crohn’s esophagitis with fistula or obstruction, or to rule out malignancy. These reports showed a 25% mortality rate, which is similar to another report by Rholl et al where two out of five patients operated on for esophageal airway fistula died after esophagectomy.

**Conclusion**

UGI-CD remains a rare aspect of the disease. Routine screening in the pediatric population has demonstrated a higher prevalence; however, it is likely under-reported in the adult population. Many adults remain asymptomatic, possibly because they are being treated for distal disease a priori. For the patients who are symptomatic, it will usually improve with medical management, the best results being with use of steroids, and more recently with biologic agents. Though most patients respond to medical therapy, if surgical intervention is needed for gastroduodenal disease it is primarily for obstruction secondary to stricture formation, perforation, or bleeding. Strictureplasty and bypass are both options with comparable morbidity, although bypass has higher reported rates of dumping syndrome and marginal ulceration. Cases of gastroduodenal fistulous disease from active distal disease may involve the stomach or duodenum and are usually managed surgically. Esophageal CD is exceptionally rare, is usually inflammatory, and mainly managed medically, but in severe cases can fistulize to surrounding structures in the mediastinum which may require the highly morbid esophagectomy.

**References**


Schwartzberg et al.


